echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Tianjing Bio and ABL Bio announce the completion of the first patient administration of TJ-L14B Phase 1 in the United States

    Tianjing Bio and ABL Bio announce the completion of the first patient administration of TJ-L14B Phase 1 in the United States

    • Last Update: 2021-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 6, Tianjing Biotechnology and ABL Bio of South Korea jointly announced that the first US phase clinical study of the bispecific antibody TJ-L14B/ABL503 jointly developed by the two parties has completed the first patient administration.


    TJ-L14B/ABL503 is a highly differentiated bispecific antibody based on PD-L1 developed by Tianjing Bio and ABL Bio.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.